Bambusa Therapeutics Inc. filed for an initial public offering to fund trials of its drugs to treat eczema and other inflammation disorders. According to reports from NDTV, the Boston-based company is working on long-acting bispecific antibodies to treat unmet needs in the more than $150 billion-a-year global immunology and inflammation market, encompassing skin, respiratory, gastroenterology and autoimmune diseases. The filing was made Friday with the US Securities and Exchange Commission, as reported by NDTV. The IPO is being led by Bank of America Corp., Evercore Inc., UBS Group AG and Cantor Fitzgerald, with Bambusa expecting its shares to trade on the Nasdaq Global Select Market under the symbol BBTX.
The company's biggest investors include Salvia Investment, RA Capital Management, entities affiliated with German billionaire Thomas Strüngmann, San Francisco-based healthcare investor BVF Partners, KKR & Co.-controlled Dawn Biopharma and Hong Kong-based INCE Capital. As reported by NDTV, co-founder Shanshan Xu, a former BioNTech executive, beneficially owns 21.5% of Bambusa. The company completed a funding round in November with participation from existing investors including RA Capital, Janus Henderson Investors and Dawn Biopharma, raising $33.1 million at a substantial valuation step-up from an $89 million round earlier that year. The financing valued the company markedly higher than the earlier round, reflecting strong investor confidence in the company's prospects.
According to the SEC filing, at the end of June, Bambusa had $71.5 million of cash and equivalents. The company had a net loss of $22.4 million on no revenue for the six months ended June 30, 2026, versus a net loss of $13.0 million on no revenue for the corresponding period a year earlier. The IPO represents the company's strategy to raise additional capital to fund its clinical trials and advance its drug development programs in the competitive biotech landscape.
Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases. As reported by NDTV, the company's lead drug candidates were acquired through this strategic transaction, positioning it to address significant unmet medical needs in the global immunology market. The company's approach focuses on long-acting bispecific antibodies, targeting multiple indications across the $150 billion global immunology and inflammation market.
